Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy

Virus Research

Volumn 66, Issue 1, 2000, Pages 13-26

  Briones, Carlos ^a   Mas, Antonio ^b   Gómez Mariano, Gema ^b   Altisent, Carmen ^c   Menéndez Arias, Luis ^b   Soriano, Vincent ^a   Domingo, Esteban ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

AIDS; HIV evolution; Mutation; Quasispecies complexity

Indexed keywords

RNA DIRECTED DNA POLYMERASE;

ADULT; ARTICLE; CASE REPORT; GENE INSERTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MUTATION; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS REPLICATION;

ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DIPEPTIDES; DNA, VIRAL; DRUG RESISTANCE, MICROBIAL; EVOLUTION, MOLECULAR; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; PHYLOGENY; PROVIRUSES; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA;

EID: 0033971425     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1702(99)00120-3     Document Type: Article

References (64)

1. Bonhoeffer S., May R.M., Shaw G.M., Nowak M.A. Virus dynamics and drug therapy. Proc. Natl. Acad. Sci. USA. 94:1997;6971-6976.
2. Boom R., Sol C.J., Salimans M.M., Jansen C.L., Wertheim-vam Dillen P.M., van der Noordaa J. Rapid and simple methods for purification of nucleic acids. J. Clin. Microbiol. 28:1990;495-503.
3. Boyer P.L., Lisziewicz J., Lori F., Hughes S.H. Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase. J. Mol. Biol. 286:1999;995-1008.
4. Buckheit, R.W., Jr., Fliakas-Boltz, V., Decker, W.D., Robertson, J.L., Stup, T.L., Pyle, C.A., White, E.L., McMahon, J.B., Currens, M.J., Boyd, M.R., Bader, J.P., 1995. Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antivir. Res. 26, 117-132.
5. Carrillo A., Stewart K.D., Sham H.L., Norbeck D.W., Kohlbrenner W.E., Leonard J.M., Kempf D.J., Molla A. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J. Virol. 72:1998;7532-7541.
6. Clarke D.K., Duarte E.A., Elena S., Moya A., Domingo E., Holland J.J. The red queen reigns in the kingdom of RNA viruses. Proc. Natl. Acad. Sci. USA. 91:1994;4821-4824.
7. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 267:1995;483-489.
8. De Antoni A., Foli A., Lisziewicz J., Lori F. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J. Infect. Dis. 176:1997;899-903.
9. de Jong J.J., Goudsmit J., Lukashov V.V., Hillebrand M.E., Baan E., Huismans R., Danner S.A., ten Veen J.H., de Wolf F., Jurriaans S. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS. 13:1999;75-80.
10. Domingo E., Sabo D.L., Taniguchi T., Weissmann C. Nucleotide sequence heterogeneity of an RNA phage population. Cell. 13:1978;735-744.
11. Domingo E. RNA virus evolution and the control of viral disease. Prog. Drug Res. 33:1989;93-133.
12. Domingo, E., Holland, J.J., 1992. Complications of RNA Heterogeneity for the Engineering of Virus Vaccines and Antiviral Agents. In: Setlow, J.K. (Ed.), Genetic Engineering, vol. 14. Plenum Press, New York, pp. 13-31.
13. Domingo E. Biological significance of viral quasispecies. Viral Hepatitis Rev. 2:1996;247-261.
14. Domingo, E., Escarmís, C., Menéndez-Arias, L., Holland, J.J., 1999. Viral quiasispecies and fitness variations. In: Domingo, E., Webster, R.G., Holland, J.J. (Eds.), Origin and Evolution of Viruses. Academic Press, San Diego, pp. 141-161.
15. Drake J.W. Rates of spontaneous mutations among RNA viruses. Proc. Natl. Acad. Sci. USA. 90:1993;4171-4175.
16. Eastman P.S., Mittler J., Kelso R. et al. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J. Virol. 72:1998;5154-5164.
17. Eigen, M., Biebricher, C., 1988. Sequence space and quasispecies distribution. In: Domingo, E., Holland, J.J., Ahlquist, P. (Eds.), RNA Genetics, vol. 3. CRC Press, Boca Raton, FL, pp. 211-245.
18. + cells per cubic millimeter. North American HIV Working Party. N. Engl. J. Med. 333:1995;1662-1669.
19. Felsenstein J. PHYLIP - Phylogeny inference package. Cladistics. 5:1989;164-166.
20. Gebauer F., de la Torre J.C., Gomes I., Mateu M.G., Barahona H., Tiraboschi B., Bergmann I., Augé de Mello P., Domingo E. Rapid selection of genetic and antigenic variants of foot-and-mouth disease virus during persistence in cattle. J. Virol. 62:1988;2041-2049.
21. Goodenow M., Huet T., Saurin W., Knok S., Sninsky J., Wain-Hobson S. HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J. Acquir. Immune Defic. Syndr. 2:1989;344-352.
22. Gulick R.M., Mellors J.W., Havlir D. et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretrovial therapy. N. Engl. J. Med. 337:1997;734-739.
23. Günthard H.F., Wong J.K., Ignacio C.C., Guatelli J.C., Riggs N.L., Havlir D.V., Richman D.D. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J. Virol. 72:1998;2422-2428.
24. + cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337, 725-733.
25. Havlir D.V., Eastman S., Gamst A., Richman D.D. Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients. J. Virol. 70:1996;7894-7899.
26. Ho D.D. Toward HIV eradication or remission: the tasks ahead. Science. 280:1998;1866-1867.
27. Holland J.J., Grabau E.A., Jones C.L., Semler B.L. Evolution of multiple genome mutations during long-term persistent infection by vesicular stomatitis virus. Cell. 16:1979;495-504.
28. Holland J.J., Spindler K., Horodyski F., Grabau E., Nichol S., VandePol S. Rapid evolution of RNA genomes. Science. 215:1982;1577-1585.
29. Holland J.J., de la Torre J.C., Steinhauer D. RNA virus populations as quasispecies. Curr. Topics Microbiol. Immunol. 176:1992;1-20.
30. Karlsson A.C., Gaines H., Sällberg M., Lindbäck S., Sönnerborg A. Reappearance of founder virus sequence in human immunodeficiency virus type 1-infected patients. J. Virol. 73:1999;6191-6196.
31. Kellam P., Bouchar C.A.B., Larder B.A. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA. 89:1992;1934-1938.
32. Kern D., Collins M., Fultz T. et al. An enhanced-sensitivity branched-DNA assay for quantification of HIV type 1 RNA in plasma. J. Clin. Microbiol. 34:1996;3196-3202.
33. Korber, B., Foley, B., Leitner, T., McCutchan, F., Hahn, B., Mellors, J.W., Myers, G., Kuiken, C. (Eds.), 1997. Human Retroviruses and AIDS. A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos National Laboratory, Los Alamos.
34. Larder B.A. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol. 75:1994;951-957.
35. Larder B.A., Kemp S.D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 246:1989;1155-1158.
36. Lech W.J., Wang G., Yang Y.L. et al. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J. Virol. 70:1996;2038-2045.
37. Mansky L.M., Temin H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:1995;5087-5094.
38. Markowitz M., Conant M., Hurley A. et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J. Infect. Dis. 177:1998;1533-1540.
39. Martínez M.A., Cabana M., Ibañez A., Clotet B., Arnó A., Ruiz L. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology. 256:1999;180-187.
40. Mellors J.W., Bazmi H.Z., Schinazi R.F., Roy B.M., Hsiou Y., Arnold E., Weir J., Mayers D.L. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob. Agents Chemoter. 39:1995;1087-1092.
41. Menéndez-Arias, L., Domingo, E., 1999. Cambios de aminoácido asociados a resistencia a inhibidores de la retrotranscriptasa y la proteasa del VIH. In: Clotet, B., Ruiz, L., Martínez-Picado, X., Menéndez-Arias, L., Gatell, J.M., Richman, D.D. (Eds.), Guia práctica para el manejo clinico de las resistencias al VIH. Grupo E, Enthers, Merck Sharp and Dohme de Espãna, S.A. pp. 215-267.
42. Meyerhans A., Cheyner R., Albert J., Seth M., Kwok S., Sninsky J., Morfeldt-Manson L., Asjö B., Wain-Hobson S. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell. 58:1989;901-910.
43. Moyle G.J. Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences. Drugs. 52:1996;168-185.
44. Nájera I., Holguín A., Quiñones-Mateu M.E., Muñoz-Fernández M.A., Nájera R., López-Galíndez C., Domingo E. pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69:1995;23-31.
45. Palmer S., Shafer R.W., Merigan T.C. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS. 13:1999;661-667.
46. Preston B.D., Dougherty J.P. Mechanisms of retroviral mutation. Trends Microbiol. 4:1996;16-21.
47. Quer J., Huerta R., Novella I.S., Tsimring L., Domingo E., Holland J.J. Reproducible nonlinear population dynamics and critical points during replicative competitions of RNA virus quasispecies. J. Mol. Biol. 264:1996;465-471.
48. Quiñones-Mateu M.E., Albright J.L., Mas A., Soriano V., Arts E.J. Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1. J. Virol. 72:1998;9002-9015.
49. Ribeiro R.M., Bonhoeffer S., Nowak M.A. The frequency of resistant mutant virus before antiviral therapy. AIDS. 26:1998;461-465.
50. Richman D.D. Resistance, drug failure, and disease progression. AIDS Res. Hum. Retrov. 10:1994;901-905.
51. Saag M., Hahn B.H., Gibbons J., Li Y., Parks E.S., Parks W.P., Shaw G.M. Extensive variation of human immunodeficiency virus type-1 in vivo. Nature (London). 334:1988;440-444.
52. Saitou N., Nei M. The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4:1987;406-425.
53. Sambrook, J., Fritsch, E.F., Marniatis, T., 1989, Molecular Cloning. A Laboratory Mannual. Cold Spring Harbour Laboratory Press, New York.
54. Schinazi R.F., Larder B.A., Mellors J.W. Mutations in retroviral genes associated with drug resistance. Int. Antivir. News. 5:1997;129-142.
55. Schmit J.-C., Cogniaux J., Hermans P., Van Vaeck C., Sprecher S., Van Reemortel B., Witvrouw M., Balzarini J., Desmyter J., De Clerq E., Vandamme A.-M. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J. Infect. Dis. 174:1996;962-968.
56. Schooley R.T., Ramirez-Ronda C., Lange J.M. et al. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. J. Infect. Dis. 173:1996;1354-1366.
57. Tachedjian G., French M., Mills J. Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 42:1998;3038-3043.
58. Tamalet C., Izopet J., Koch N., Fantini J., Yahi N. Stable rearrangements of the β3-β4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy. AIDS. 12:1998;F161-F166.
59. Temin, H.M., 1993. The high rate of retrovirus variation results in rapid evolution. In: Morse S.S. (Ed.), Emerging Viruses. Oxford University Press. Oxford, pp. 219-225.
60. Thompson J.D., Higgins D.G., Gibson T.J. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice. Nucl. Acids Res. 22:1994;4673-4680.
61. Winters M.A., Coolley K.L., Girard Y.A., Levee D.J., Hamdan H., Shafer R.W., Katzenstein D.A., Merigan T.C. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J. Clin. Invest. 102:1998;1769-1775.
62. Wodarz, D., Nowak, M.A., 1999. Dynamics of HIV pathogenesis and treatment. In: Domingo, E., Webster, R.G., Holland, J.J. (Eds.), Origin and Evolution of Viruses. Academic Press, San Diego, pp. 197-223.
63. Wong J.K., Hezareh M., Günthard H.F., Havlir D.V., Ignacio C.C., Spina C.A., Richman D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 278:1997;1291-1295.
64. Wyatt C.A., Andrus L., Brotnan B., Huang F., Lee D.-H., Prince A.M. Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection. J. Virol. 72:1998;1725-1730.